Syndax Pharmaceuticals, Inc.
SNDX
$19.84
$0.763.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 12.22% | -5.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.22% | -5.62% | |||
| Cost of Revenue | 15.89% | -24.42% | |||
| Gross Profit | -54.40% | 126.83% | |||
| SG&A Expenses | 10.51% | -24.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.85% | -24.54% | |||
| Operating Income | -16.94% | 45.32% | |||
| Income Before Tax | -15.68% | 37.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.68% | 37.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.68% | 37.26% | |||
| EBIT | -16.94% | 45.32% | |||
| EBITDA | -16.94% | 45.32% | |||
| EPS Basic | -14.73% | 37.90% | |||
| Normalized Basic EPS | -14.73% | 37.90% | |||
| EPS Diluted | -14.73% | 37.90% | |||
| Normalized Diluted EPS | -14.73% | 37.90% | |||
| Average Basic Shares Outstanding | 0.83% | 1.03% | |||
| Average Diluted Shares Outstanding | 0.83% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||